Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on December 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Supernus Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ:SUPN traded down $1.23 on Thursday, reaching $50.58. 290,681 shares of the company traded hands, compared to its average volume of 601,094. The business’s 50-day simple moving average is $47.82 and its 200 day simple moving average is $44.77. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $57.65. The stock has a market capitalization of $2.90 billion, a P/E ratio of -148.73, a price-to-earnings-growth ratio of 0.50 and a beta of 0.67.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company had revenue of $170.00 million during the quarter, compared to the consensus estimate of $175.82 million. During the same quarter in the previous year, the firm posted $0.69 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Supernus Pharmaceuticals by 68.1% in the first quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after purchasing an additional 4,729 shares during the period. AQR Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after buying an additional 22,182 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Supernus Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after buying an additional 1,297 shares during the period. Millennium Management LLC increased its stake in shares of Supernus Pharmaceuticals by 370.5% in the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SUPN shares. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. TD Cowen raised their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Zacks Research cut Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Finally, Bank of America started coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $61.60.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Frank Mottola sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.80% of the stock is currently owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.